XML 23 R6.htm IDEA: XBRL DOCUMENT v3.7.0.1
Unaudited Statements of Cash Flows - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Operating Activities    
Net loss $ (65,326) $ (66,246)
Adjustments to reconcile net loss to net cash used in operating activities    
Depreciation 1,393 352
Amortization of premium and discounts on investment securities 137 331
Deferred income taxes (8) 22,853
Share-based compensation 11,052 16,641
Changes in operating assets and liabilities:    
Due from Novartis Pharma AG 2,857 (25,808)
Income tax receivable (52) (20,863)
Prepaid expense and other current assets 392 187
Accrued interest receivable 275 147
Other assets 416 (3)
Accrued research and development expenses (34,553) 6,331
Accounts payable and accrued expenses (5,764) (4,249)
Deferred revenue (3,323) 364
Net cash used in operating activities (92,504) (69,963)
Investing Activities    
Purchase of marketable securities (12,014) (12,003)
Maturities of marketable securities 111,459 50,500
Purchase of property and equipment 0 (149)
Net cash provided by (used in) investing activities 99,445 38,348
Financing Activities    
Proceeds from stock option/employee stock purchase plan exercises 46 3,808
Net cash provided by financing activities 46 3,808
Net change in cash and cash equivalents 6,987 (27,807)
Cash and cash equivalents    
Beginning of period 133,930 221,861
End of period 140,917 194,054
Supplemental disclosures of non-cash information related to investing activities    
Change in unrealized gain (loss) on available for sale securities, net of tax $ 26 $ 355